In-111 ibritumomab scintigraphy (planar and SPECT) and FDG PET/CT before Y-90 ibritumomab treatment in a patient with mantle cell lymphoma.
We report the case of a 75-year-old man, in whom Y-90 ibritumomab was requested because of relapse of blastoid variant mantle cell lymphoma diagnosed in 1995. Before Y-90 ibritumomab treatment, FDG PET and In-111 ibritumomab scintigraphy with planar views at 24 hours, 48 hours, and 5 days, including SPECT, were performed. Discordant information between both examinations was observed as, in addition to the lesions detected by In-111 ibritumomab imaging, FDG PET detected lesions that did not take up the ibritumomab. The discrepancy shown by both radiotracers has to be kept in mind before planning treatment with Y-90 ibritumomab, and for the correct evaluation of treatment response.
Jiménez-Bonilla
Julio Francisco
JF
Nuclear Medicine Service, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Santander, Spain. jjimenez@humv.es
Quirce
Remedios
R
Banzo
Ignacio
I
Martínez-Rodríguez
Isabel
I
Sainz-Esteban
Aurora
A
Barragán
Jorge Enrique
JE
López-Cordovilla
Juan José
JJ
Carril
José Manuel
JM
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D006801:Humans; D007205:Indium Radioisotopes / Q000493:pharmacokinetics; D020522:Lymphoma, Mantle-Cell / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D049268:Positron-Emission Tomography; D016499:Radioimmunotherapy; D015899:Tomography, Emission-Computed, Single-Photon; D014057:Tomography, X-Ray Computed
D000911:Antibodies, Monoclonal; D007205:Indium Radioisotopes; D019788:Fluorodeoxyglucose F18; C422802:ibritumomab tiuxetan